IHS Chemical Week

EnviroTech :: Biotech

KaloBios Signs Research and Commercial Agreement with BioWa and Lonza

12:08 AM MST | February 8, 2011 | Deepti Ramesh

Lonza says that biopharmaceutical company KaloBios Pharmaceuticals (South San Francisco, CA) has signed a research and commercial agreement with biotech company BioWa (Princeton, NJ), a subsidiary of Kyowa Hakko Kirin (Tokyo), and Lonza, to use their Potelligent CHOK1SV cell line for the development and production of KaloBios’ Humaneered antibodies. Potelligent CHOK1SV is a new host cell line for manufacturing recombinant antibodies that combines BioWa’s engineered glycosylation Potelligent technology with Lonza’s proprietary GS Gene Expression...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Not an IHS Chemical Week subscriber yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine a year in print or digital format
  • Real time news and analysis on chemweek.com 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now


contact us | about us | privacy policy | sitemap

ihsCopyright © IHS, Inc.All rights reserved.Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa